Target the gene, silence the disease
Location: United States, Kentucky, Lexington
Employees: 201-500
Total raised: $45M
Founded date: 1989
Investors 1
| Date | Name | Website |
| - | Aquilo Cap... | aquilocapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.08.2016 | - | $45M | - |
Mentions in press and media 17
| Date | Title | Description |
| 21.12.2022 | Arrowhead Pharmaceuticals Receives $25M Payment | - |
| 14.10.2022 | Wisconsin-Japan Biohealth Summit showcases international collaboration | Guest post contributed by BioForward Across the globe, life science technology advancements are accelerating to promote better health. The recent Wisconsin-Japan Biohealth Summit, designed to raise awareness of current collaborations while ... |
| 12.07.2022 | An Epic in miniature: CRISPR pioneer's startup reels in $55M to use tiny Cas for epigenetic engineering | CRISPR co-inventor Stanley Qi, Ph.D., is out with a new biotech that wants to make a big splash by going small. The startup, Epic Bio, corralled a investor syndicate willing to bet $55 million on its vision to use the smallest known Cas pro... |
| 18.05.2022 | Wisconsin’s biotech strength leverages major drug company expansion | Concept drawing of Arrowhead Pharmaceuticals’ new Verona campus When Arrowhead Pharmaceuticals embarked on a $220 million expansion in Wisconsin, WEDC partnered with the firm to help it become a reality. The project, which has broken ground... |
| 11.05.2022 | Wisconsin giving Arrowhead Pharmaceuticals some cheddar as their new manufacturing site receives several million in state and local tax benefits | Arrowhead Pharmaceuticals is getting a leg up from Wisconsin officials on a new building project. The company has outlined a set of incentives that have become quite common as states look to compete for new manufactur... |
| 25.04.2022 | Vivo Capital pitches $60M to bring Arrowhead's RNAi meds to China via joint venture | Generally speaking, any biotech hoping to have a presence in China has a number of options. One could out-license its drugs to one of the transpacific players set up explicitly to be a bridge between Western medicines an... |
| 23.12.2021 | Arrowhead adds newest facility to its Midwest hub in RNAi drug production push | Arrowhead Pharmaceuticals has purchased 13 acres of land in Wisconsin’s Verona Technology Park and will build a 140,000-square-foot drug manufacturing facility. The company will spend between $200 million and $250 mil... |
| 25.06.2021 | Arrowhead Pharmaceuticals : EASL 2021 JNJ-3989 Presentation | Hepatitis B virus Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Edward Gane1, Stephen Locarnini... |
| 25.06.2021 | Arrowhead Pharmaceuticals : EASL 2021 JNJ-3989 PK Safety Presentation | 1416 Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically‑impaired Participants Thomas N. Kakuda1, Atef Halabi2, Carine Guinard-Azadian3, Katja Nedoschinsky3, Julius Nango... |
| 15.12.2020 | Arrowhead Pharmaceuticals : NLA 2020 ARO-APOC3 | Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia P Clifton1, D Sullivan2, J Baker3... |
Show more